<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="publisher-id">MEDI</journal-id>
      <journal-title-group>
        <journal-title>Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0025-7974</issn>
      <issn pub-type="epub">1536-5964</issn>
      <publisher>
        <publisher-name>Wolters Kluwer Health</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">28178157</article-id>
      <article-id pub-id-type="pmc">5313014</article-id>
      <article-id pub-id-type="publisher-id">MD-D-16-04954</article-id>
      <article-id pub-id-type="doi">10.1097/MD.0000000000006062</article-id>
      <article-id pub-id-type="art-access-id">06062</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>5700</subject>
        </subj-group>
        <subj-group>
          <subject>Research Article</subject>
          <subject>Clinical Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy</article-title>
        <subtitle>Case report and review of literature</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Montanier</surname>
            <given-names>Nathana&#xEB;lle</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
          <xref rid="cor1" ref-type="corresp">
            <sup>&#x2217;</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Joubert-Zakeyh</surname>
            <given-names>Juliette</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff2">
            <sup>b</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>P&#xE9;torin</surname>
            <given-names>Caroline</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff3">
            <sup>c</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Montoriol</surname>
            <given-names>Pierre Fran&#xE7;ois</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff4">
            <sup>d</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maqdasy</surname>
            <given-names>Salwan</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
          <xref ref-type="aff" rid="aff5">
            <sup>e</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kelly</surname>
            <given-names>Antony</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff6">
            <sup>f</sup>
          </xref>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Staege.</surname>
            <given-names>Martin S.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>CHU Clermont-Ferrand, Service d&#x2019;endocrinologie, diab&#xE9;tologie et maladies m&#xE9;taboliques</aff>
      <aff id="aff2"><label>b</label>CHU Clermont-Ferrand, Service d&#x2019;anatomopathologie</aff>
      <aff id="aff3"><label>c</label>CHU Clermont-Ferrand, Service de chirurgie et oncologie digestive</aff>
      <aff id="aff4"><label>d</label>Centre de Lutte Contre le Cancer Jean Perrin, Service de radiologie, Clermont-Ferrand</aff>
      <aff id="aff5"><label>e</label>UMR CNRS 6293, INSERM U1103, Universit&#xE9; Clermont-Auvergne, G&#xE9;n&#xE9;tique Reproduction et D&#xE9;veloppement, Aubiere</aff>
      <aff id="aff6"><label>f</label>Centre de Lutte Contre le Cancer Jean Perrin, Service de M&#xE9;decine nucl&#xE9;aire, Clermont-Ferrand, France.</aff>
      <author-notes id="cor1">
        <corresp><label>&#x2217;</label>Correspondence: Nathana&#xEB;lle Montanier, CHU Gabriel Montpied, 58, Rue Montalembert, 63000 Clermont-Ferrand, France (e-mail: <email>nathanaelle.montanier@etu.udamail.fr</email>).</corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <volume>96</volume>
      <issue>6</issue>
      <elocation-id>e6062</elocation-id>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>7</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>28</day>
          <month>11</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>1</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2017 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement>
        <copyright-year>2017</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="medi-96-e6062.pdf"/>
      <abstract>
        <title>Abstract</title>
        <sec>
          <title>Rationale:</title>
          <p>Pancreatic neuroendocrine tumors (pNET) are rare slowly growing tumors with a high metastatic potential. Peptide receptor radionuclide therapy (PRRT) with radiolabeled analogues has been developed as a new tool for the management of metastatic well-differentiated (grade 1 and 2) neuroendocrine tumors expressing somatostatin receptor (SSTR2). Chemotherapy is the mainstay in the management of grade 3 (G3) unresectable pancreatic neuroendocrine carcinoma (pNEC). To date, no study has evaluated the efficacy of PRRT in such tumors.</p>
        </sec>
        <sec>
          <title>Diagnoses and interventions:</title>
          <p>We describe a case of a progressive G3 pNEC with huge liver metastases successfully treated with PRRT (<sup>177</sup>Lu DOTATATE).</p>
        </sec>
        <sec>
          <title>Outcomes:</title>
          <p>Complete remission was obtained for 3 years. Indeed, the mitotic index was low (as G2 tumors) but with a very high Ki-67 index (45%&#x2013;70%). Such discordance between the proliferative markers should consider the use of PRRT before chemotherapy in unresectable metastatic G3 tumors expressing SSTR2.</p>
        </sec>
        <sec>
          <title>Lessons:</title>
          <p>This case supports the hypotheses highlighting the heterogeneity of G3 pNEC. The latter should be subdivided into 2 distinct categories: proliferation-discordant (well differentiated) and concordant (poorly differentiated) NEC. PRRT could be suggested for the former group before the conventional chemotherapy.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>discordance</kwd>
        <kwd>neuroendocrine carcinoma</kwd>
        <kwd>pNET</kwd>
        <kwd>proliferative markers</kwd>
        <kwd>PRRT</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <label>1</label>
      <title>Introduction</title>
      <p>Pancreatic neuroendocrine tumors (pNET) are rare slowly growing tumors with a high metastatic potential. Distant metastases, mainly to the liver, are present in about 60% of the cases at diagnosis.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> Biotherapy and chemotherapy are the main steps in the management of inoperable metastatic tumors.<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup> Since 2 decades, peptide receptor radionuclide therapy (PRRT) with radiolabeled analogues has been developed as a new tool for the management of metastatic well-differentiated neuroendocrine tumors (grades 1 and 2 according to WHO and ENETS classification of NET), with promising results. However, because of lack of prospective studies, it is considered only as a second-line therapy for G1 and G2 pNET.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> Indeed, recent studies demonstrated the benefits of PRRT as a first-line treatment for progressive diseases.<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>]</sup> To date, no study has evaluated the efficacy of PRRT in G3 NET or neuroendocrine carcinoma (NEC). The latter are poorly differentiated tumors for which chemotherapy is indicated as a first-line therapeutic option. Recently, NECs were described to be more heterogeneous and their prognosis seems variable.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> Indeed, the histopathological study of NEC is characterized by a high Ki-67 and/or mitotic index according to ENETS and WHO criteria. Some of them could have very high Ki-67 with low mitotic index or inversely. Discordance between these proliferative markers could be in favor of a better prognosis compared to tumors with both markers elevated. In this article, we describe a case of progressive poorly differentiated metastatic pNEC with a complete remission for &gt;3 years, thanks to PRRT! Furthermore, we review further predictive factors of good response to PRRT besides somatostatin receptor (SSTR2) expression. The proliferative discordance in our case could be one of these factors. This element should consider the use of PRRT in unresectable metastatic pNEC expressing SSTR2. This case supports the few theories suggesting that G3 pNEC should be subdivided into 2 distinct categories: well (proliferation-discordant) and true poorly differentiated ones (proliferation concordant with both Ki-67 and mitotic index over 20). PRRT could be suggested for the former group before conventional chemotherapy.</p>
    </sec>
    <sec>
      <label>2</label>
      <title>Case report</title>
      <p>In 2007, a 57-year-old woman has presented with abdominal discomfort. The computed tomography identified a 45-mm-diameter tumor occupying both the body and the tail of the pancreas, invading the splenic vessels, with a secondary lesion of 20&#x200A;mm in the segment IV of the liver. She did not have secretory symptoms. Surgical excision of the pancreatic and liver masses was decided owing to the doubtful histopathological results on the endoscopic biopsy and the excellent performance of the patient. The final histopathological analysis revealed a poorly differentiated neuroendocrine carcinoma of the pancreas with 4 mitoses in 10 high-power fields and a very high Ki-67 (45%&#x2013;70% in some focal areas). The tumor revealed a positive immunostaining for CK19 and Vimentin (Fig. <xref ref-type="fig" rid="F1">1</xref>). It was graded as NEC (G3) and staged as T3N0M1 according to ENETS-2006 classification.<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> The postoperative somatostatin receptor scintigraphy (OctreoScan) revealed massive liver invasion by multiple lesions overexpressing somatostatin receptors (grade 3 isotope uptake). She received a treatment by somatostatin analogues (Octreotide LAR 20&#x200A;mg) that temporarily stabilized the lesions. In May 2009, she presented a symptomatic carcinoid syndrome in parallel with disease progression; new liver lesions on segment VI and VIII appeared. Despite medical treatment with somatostatin analogues, the liver metastases progressed and invaded up to 50% of the liver. Owing to her excellent physical status (Karnofsky Performance Score&#x200A;=&#x200A;100%) and to the intensive fixation of the tumor on the OctreoScan, it was decided to manage her with PRRT using <sup>177</sup>Lutetium-radiolabeled somatostatin analogue (DOTATATE) in the Erasmus Center of Rotterdam. From September 2010 until March 2011, she received 4 sessions of 7.5GBq, every 2 months, each session was followed by an injection of Lanreotide LAR 120&#x200A;mg. The Chromogranin A decreased progressively from 209&#x200A;&#x3BC;g/L in the pre therapeutic stage (July 2010) to 39&#x200A;&#x3BC;g/L at the end of the treatment. In March 2012, the liver metastases completely disappeared on tomography and OctreoScan, suggesting a complete response to <sup>177</sup>Lu DOTATATE (Fig. <xref ref-type="fig" rid="F2">2</xref>). After 36 months of complete response, several liver metastases reappeared. Chemotherapy with 5FU-ZANOSAR was administered together with Lanreotide LP 120&#x200A;mg, before switching to Sunitinib because of disease progression.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Characterization of pancreatic neuroendocrine carcinoma (G3) with discordant proliferative markers. E and F represent the markers of aggressiveness (please see<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup>). (A) Hematoxylin-eosin (125&#xD7;) showing normal tissue (N) separated from the tumor (T) by a dashed line. Note the presence of vascular emboli (v.e). (B) Immunohistochemical study showing chromogranin A staining within the tumor (400&#xD7;). (C) Haematoxylin-eosin (400&#xD7;) showing the mitotic rate within the tumor (arrow). The number of mitoses per field was &lt;5. (D) Immunohistochemical evaluation of Ki-67 (100x) expression that varies from 45% to 75%. (E) Immunohistochemical study showing positive reactivity for CK19 (400&#xD7;). (F) Immunohistochemical study showing positive reactivity for Vimentin (200&#xD7;).</p>
        </caption>
        <graphic xlink:href="medi-96-e6062-g001"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Complete remission of liver metastases after 4 cures of peptide receptor radionuclide therapy with <sup>177</sup>Lu DOTATATE confirmed on somatostatin receptor scintigraphy (OctreoScan) and computed tomography (CT) imaging. In the column on the left, note the high burden of liver metastases overexpressing SSTR2, with a high score of tumor uptake (grade 3 fixation) on Octreoscan. CT shows an enhanced contrast uptake during the arterial and portal time with diffuse liver damage. In the second column, complete remission of the metastases after 4 cures of <sup>177</sup>Lu DOTATATE with a consequent persistence of scars in the segment VIII, without contrast uptake on CT imaging and no fixation on OctreoScan.</p>
        </caption>
        <graphic xlink:href="medi-96-e6062-g002"/>
      </fig>
      <p>Informed consent was obtained from the patient for publication of this case report.</p>
    </sec>
    <sec>
      <label>3</label>
      <title>Discussion</title>
      <p>The incidence of pNET is about 2 per 1,000,000 persons, and represents about 20% of the neuroendocrine tumors.<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R8" ref-type="bibr">8</xref>]</sup> The median survival of the nonfunctional pNETs is about 38 months, with 5-year survival obtained in 43% of the patients. The presence of distant metastases and the degree of differentiation are the most powerful predictors of survival.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> Indeed, Grade 3 or poorly differentiated NEC (&gt;20 mitoses per 10 high-power fields and/or a Ki-67 index of &gt;20%) are of poor prognosis; the 5-year survival rates vary between 6% and 11%.<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]</sup> Such tumors are disseminated in 50% to 70% of cases at diagnosis and are rarely accessible to surgery or locoregional methods.<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> Systemic chemotherapy with cisplatin/etoposide remains the standard management of grade 3 NEC with an objective response obtained in 41% of the patients and a median survival of 9.2 months.<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup></p>
      <p>In the 1990s, PRRT with radiolabeled somatostatin analogues was introduced into the management of NETs, offering promising results in the well-differentiated metastatic tumors. Radiolabeled somatostatin analogue consists of a radionucleotide (<sup>111</sup>Indium, <sup>90</sup>Ytrium, or <sup>177</sup>Lutetium) linked to a chelator (DTPA or DOTA) and bound to a somatostatin analogue (Octreotide or Octreotate). It delivers radionuclides to its target (tumors expressing somatostatin receptors). To-date, <sup>177</sup>Lu-DOTA<sup>0</sup> [Tyr<sup>3</sup>]-Octreotate stands out as the treatment of choice when PRRT strategy is adopted, thanks to its higher affinity to SSTR2.<sup>[<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref>]</sup></p>
      <p>According to the European Neuroendocrine Tumor Society (ENETS), PRRT is recommended as a second intention treatment, after the medical biotherapy (SST analogues), in patients with G1/G2 NETs strongly expressing SSTR2 on pretherapeutic imaging.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup></p>
      <p>Several studies reported an excellent response to <sup>177</sup>Lu-Octreotate during the management of NETs. A prospective study of Kwekkeboom et al evaluated the efficacy of <sup>177</sup>Lu-Octreotate in 310 patients with gastroenteropancreatic NETs (GEP-NET). Among them, 72 had pNET; 4 patients with pNET (6%) showed a complete response and 43 (60%) reached an objective response rate (ORR). However, no subgroup information about tumor grades was available.<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup> We analyzed all the articles studying PRRT efficacy in the NETs and the data are summarized in the table. Indeed, the objective response rate was obtained for 57% of the patients, whereas only 17% of NETs progressed with PRRT (Table <xref ref-type="table" rid="T1">1</xref>).</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Main studies assessing the efficacy of peptide receptor radionuclide therapy with <sup>177</sup>Lu in neuroendocrine tumors including the pancreatic neuroendocrine tumors.</p>
        </caption>
        <graphic xlink:href="medi-96-e6062-g003"/>
      </table-wrap>
      <p>Compared to the conventional chemotherapy, PRRT seems to be safer and well tolerated with fewer adverse effects. Indeed, <sup>177</sup>Lu-DOTATATE safety was studied in 504 patients with GEP-NET.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> Digestive and hematological side effects were reported in 25% and 3.6% of patients, respectively. Serious adverse effects were rarely reported.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup></p>
      <p>PRRT offers better results in terms of efficacy in G1-G2 NETs than chemotherapy. The median time to progression-free survival (PFS) in PRRT-treated patients is about 34 months, and the overall survival rate up to 53 months.<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> The response to PRRT was maximal in G1/G2 GEP-NETs (Ki-67 &lt;20%).<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> In pNEC treated by chemotherapy, PFS and overall survival do not exceed 8 to 18 and 20 to 40 months, respectively.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> These data suggest the efficacy of PRRT in the management of metastatic pNET compared to chemotherapy. However, it is important to emphasize that a great heterogeneity exists between different study populations and we compare different populations with different tumor grades. Randomized controlled trials comparing PRRT and chemotherapy are necessary to confirm the superiority of PRRT.</p>
      <p>To date, PRRT is not recommended in G3 pNEC.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> A case of response to PRRT has been reported in a poorly differentiated neuroendocrine carcinoma of unknown primary progressing despite 2 different chemotherapy regimens.<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> In a retrospective study assessing the impact of Ki-67 proliferation index on the response to PRRT, disease progression has been reported in 71% of the G3 subpopulation of GEP-NEC (5/7 patients G3, with only one patient with a stable disease and another with partial response).<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> But, in this cohort, only 3 pancreatic NEC were included, and the response in such tumors was not detailed, but seemed better in pNEC than in the other gastrointestinal NEC. Moreover, despite a Ki-67 &gt;30% in 2 patients, their response to PRRT was better than the 5 other patients. This suggests that Ki-67 alone is not sufficient to predict the bad prognosis of such tumors and their response to PRRT.</p>
      <p>Despite the presence of poor prognostic factors like high hepatic burden of &#x2265;25%, positive staining for CK-19 and Vimentin (Fig. <xref ref-type="fig" rid="F1">1</xref>), and grade 3 NEC, surprisingly, our patient successfully responded to PRRT while belonging to the poorly differentiated G3 group and presenting aggressive components in immunochemistry.<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>]</sup> Thus, the drastic response to PRRT in our case highlights the importance of Octreoscan fixation and the proliferative discordance. Indeed, a high uptake of the radiolabeled diagnostic isotope (<sup>111</sup>In-DTPA) constitutes a predictive factor of response to PRRT. Kweekkeboom and Ezziddin separately identified a relationship between the chances of tumor remission after treatment with <sup>177</sup>Lu-DOTATE and the radioisotope uptake degree on pretherapeutic Octreoscan.<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R11" ref-type="bibr">11</xref>]</sup> Second, the dissociation between the proliferative markers (the mitotic index and Ki-67 rate) in our case supports few data demonstrating the heterogeneity of G3 tumors.<sup>[<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R19" ref-type="bibr">19</xref>]</sup> Many studies highlighted the importance of Ki-67 rate to predict the prognosis of NETs; PFS was longer for G2 tumors with Ki-67 &lt;10% compared to those with Ki-67 &gt;10% (31 vs. 19 months).<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> Furthermore, 2 distinct categories of tumors are described within the G3 tumors: differentiated but highly proliferating NEC with Ki-67 between 20% and 50% and true poorly differentiated NEC with Ki-67 typically &gt;50%.<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> Indeed, our patient belonged to the second group, but with a discordant low mitotic index. Recently, Basturk et al studied the clinical course and pathological features of 19 patients with grade discordant G3 pNEC (mitotic index from 2 to 20 with Ki-67 index &gt;20%), compared to 53 patients with grade concordant G2 pNET (both mitotic count and Ki-67 index &lt;20%) and to 43 true poorly differentiated pNECs. Patients with grade discordant pNET had significantly longer survival time compared to patients with poorly differentiated NEC (54 vs. 11 months). Thus, grade 3 NECs are heterogeneous and could have a variable prognosis.<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup> The discordance between the proliferative markers could classify such patients in the G2 group. These data suggest that G3 NEC should be reclassified to restratify the management opportunities including PRRT.</p>
    </sec>
    <sec>
      <label>4</label>
      <title>Conclusion</title>
      <p>PRRT was successful to obtain a significant disease remission in a patient with a pancreatic neuroendocrine carcinoma despite an important tumor burden within the liver. This is the first case highlighting the efficacy of PRRT to treat metastatic G3 pNEC and revealing the prognostic significance of the proliferative discordance. Randomized controlled trials are needed to confirm the superiority of PRRT over chemotherapy in the proliferative discordant pNEC expressing SSTR2. This case demonstrates the heterogeneity of G3 tumors, separating them into well and poorly differentiated ones. Such proliferative discordance greatly influenced the prognosis in our patient and requires further analyses to reclassify such tumors as G2 rather than G3.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="abbr">
        <p>Abbreviations: 5-FU = 5-fluoro-uracil, CK-19 = cytokeratin 19, ENETS = European Neuroendocrine Tumor Society, GEP-NET = gastro-entero-pancreatic-neuroendocrine tumors, Grade 1, 2, 3 = G1, G2, G3, LAR = long acting release, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, ORR = objective response rate, PFS = progression-free survival, pNEC = pancreatic neuroendocrine carcinoma, pNET = pancreatic neuroendocrine tumor, PRRT = peptide receptor radionuclide therapy, SSTR2 = Somatostatin receptor of type 2, WHO = World Health Organization.</p>
      </fn>
      <fn fn-type="COI-statement">
        <p>The authors report no conflicts of interest.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>[1]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halfdanarson</surname><given-names>TR</given-names></name><name><surname>Rabe</surname><given-names>KG</given-names></name><name><surname>Rubin</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival</article-title>. <source>Ann Oncol</source>
<year>2008</year>;<volume>19</volume>:<fpage>1727</fpage>&#x2013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">18515795</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>[2]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Dey</surname><given-names>C</given-names></name><name><surname>Kennecke</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Consensus recommendations for the diagnosis and management of pancreatic neuroendocrine tumors: guidelines from a Canadian National Expert Group</article-title>. <source>Ann Surg Oncol</source>
<year>2015</year>;<volume>22</volume>:<fpage>2685</fpage>&#x2013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">25366583</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>[3]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falconi</surname><given-names>M</given-names></name><name><surname>Bartsch</surname><given-names>DK</given-names></name><name><surname>Eriksson</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors</article-title>. <source>Neuroendocrinology</source>
<year>2012</year>;<volume>95</volume>:<fpage>120</fpage>&#x2013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">22261872</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>[4]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezziddin</surname><given-names>S</given-names></name><name><surname>Khalaf</surname><given-names>F</given-names></name><name><surname>Vanezi</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours</article-title>. <source>Eur J Nucl Med Mol Imaging</source>
<year>2014</year>;<volume>41</volume>:<fpage>925</fpage>&#x2013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">24504504</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>[5]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwekkeboom</surname><given-names>DJ</given-names></name><name><surname>de Herder</surname><given-names>WW</given-names></name><name><surname>Kam</surname><given-names>BL</given-names></name><etal/></person-group>
<article-title>Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival</article-title>. <source>J Clin Oncol</source>
<year>2008</year>;<volume>26</volume>:<fpage>2124</fpage>&#x2013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">18445841</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>[6]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V&#xE9;layoudom-C&#xE9;phise</surname><given-names>F-L</given-names></name><name><surname>Duvillard</surname><given-names>P</given-names></name><name><surname>Foucan</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Are G3 ENETS neuroendocrine neoplasms heterogeneous?</article-title>
<source>Endocr Relat Cancer</source>
<year>2013</year>;<volume>20</volume>:<fpage>649</fpage>&#x2013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">23845449</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>[7]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rindi</surname><given-names>G</given-names></name><name><surname>Kl&#xF6;ppel</surname><given-names>G</given-names></name><name><surname>Alhman</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system</article-title>. <source>Virchows Arch</source>
<year>2006</year>;<volume>449</volume>:<fpage>395</fpage>&#x2013;<lpage>401</lpage>.<pub-id pub-id-type="pmid">16967267</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>[8]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lepage</surname><given-names>C</given-names></name></person-group>
<article-title>Incidence and management of malignant digestive endocrine tumours in a well defined French population</article-title>. <source>Gut</source>
<year>2004</year>;<volume>53</volume>:<fpage>549</fpage>&#x2013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">15016750</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>[9]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strosberg</surname><given-names>JR</given-names></name><name><surname>Cheema</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Prognostic Validity of a Novel American Joint Committee on Cancer Staging Classification for Pancreatic Neuroendocrine Tumors</article-title>. <source>J Clin Oncol</source>
<year>2011</year>;<volume>29</volume>:<fpage>3044</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21709192</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>[10]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorbye</surname><given-names>H</given-names></name><name><surname>Strosberg</surname><given-names>J</given-names></name><name><surname>Baudin</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Gastroenteropancreatic high-grade neuroendocrine carcinoma: Neuroendocrine Carcinoma</article-title>. <source>Cancer</source>
<year>2014</year>;<volume>120</volume>:<fpage>2814</fpage>&#x2013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">24771552</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>[11]</label>
        <mixed-citation publication-type="book"><publisher-name>Elsevier</publisher-name>, <person-group person-group-type="author"><name><surname>Kwekkeboom</surname><given-names>DJ</given-names></name><name><surname>de Herder</surname><given-names>WW</given-names></name><name><surname>van Eijck</surname><given-names>CH</given-names></name></person-group>
<article-title>Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors</article-title>. <source>Seminars in Nuclear Medicine</source>
<year>2010</year>;<comment>78&#x2013;88; <ext-link ext-link-type="uri" xlink:href="http://trafficlight.bitdefender.com/info?url=http%253A//www.sciencedirect.com/science/article/pii/S0001299809001020%26language=fr_FR">http://trafficlight.bitdefender.com/info?url=http%3A//www.sciencedirect.com/science/article/pii/S0001299809001020&amp;language=fr_FR</ext-link>. Accessed August 8, 2015</comment>.</mixed-citation>
      </ref>
      <ref id="R12">
        <label>[12]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>BLR</given-names></name><name><surname>Teunissen</surname><given-names>JJM</given-names></name><name><surname>Krenning</surname><given-names>EP</given-names></name><etal/></person-group>
<article-title>Lutetium-labelled peptides for therapy of neuroendocrine tumours</article-title>. <source>Eur J Nucl Med Mol Imaging</source>
<year>2012</year>;<volume>39</volume>:<fpage>103</fpage>&#x2013;<lpage>12</lpage>.</mixed-citation>
      </ref>
      <ref id="R13">
        <label>[13]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sansovini</surname><given-names>M</given-names></name><name><surname>Severi</surname><given-names>S</given-names></name><name><surname>Ambrosetti</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Treatment with the radiolabelled somatostatin analog 177Lu-DOTATATE for advanced pancreatic neuroendocrine tumors</article-title>. <source>Neuroendocrinology</source>
<year>2013</year>;<volume>97</volume>:<fpage>347</fpage>&#x2013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">23392072</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>[14]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodei</surname><given-names>L</given-names></name><name><surname>Cremonesi</surname><given-names>M</given-names></name><name><surname>Grana</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>Peptide receptor radionuclide therapy with <sup>177</sup>Lu-DOTATATE: the IEO phase I-II study</article-title>. <source>Eur J Nucl Med Mol Imaging</source>
<year>2011</year>;<volume>38</volume>:<fpage>2125</fpage>&#x2013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">21892623</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>[15]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezziddin</surname><given-names>S</given-names></name><name><surname>Opitz</surname><given-names>M</given-names></name><name><surname>Attassi</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy</article-title>. <source>Eur J Nucl Med Mol Imaging</source>
<year>2011</year>;<volume>38</volume>:<fpage>459</fpage>&#x2013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">20852858</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>[16]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garske</surname><given-names>U</given-names></name><name><surname>Sandstr&#xF6;m</surname><given-names>M</given-names></name><name><surname>Johansson</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Lessons on tumour response: imaging during therapy with <sup>177</sup> Lu-DOTA-octreotate. A case report on a patient with a large volume of poorly differentiated neuroendocrine carcinoma</article-title>. <source>Theranostics</source>
<year>2012</year>;<volume>2</volume>:<fpage>459</fpage>&#x2013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">22768026</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>[17]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezziddin</surname><given-names>S</given-names></name><name><surname>Attassi</surname><given-names>M</given-names></name><name><surname>Yong-Hing</surname><given-names>CJ</given-names></name><etal/></person-group>
<article-title>Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate</article-title>. <source>J Nucl Med</source>
<year>2014</year>;<volume>55</volume>:<fpage>183</fpage>&#x2013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">24434296</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>[18]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simtniece</surname><given-names>Z</given-names></name><name><surname>Vanags</surname><given-names>A</given-names></name><name><surname>Strumfa</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Original paper Morphological and immunohistochemical profile of pancreatic neuroendocrine neoplasms</article-title>. <source>Pol J Pathol</source>
<year>2015</year>;<volume>2</volume>:<fpage>176</fpage>&#x2013;<lpage>94</lpage>.</mixed-citation>
      </ref>
      <ref id="R19">
        <label>[19]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basturk</surname><given-names>O</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Tang</surname><given-names>LH</given-names></name><etal/></person-group>
<article-title>The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms</article-title>. <source>Am J Surg Pathol</source>
<year>2015</year>;<volume>39</volume>:<fpage>683</fpage>&#x2013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">25723112</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>[20]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>MD</given-names></name><name><surname>Balci</surname><given-names>S</given-names></name><name><surname>Saka</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Neuroendocrine tumors of the pancreas: current concepts and controversies</article-title>. <source>Endocr Pathol</source>
<year>2014</year>;<volume>25</volume>:<fpage>65</fpage>&#x2013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">24430597</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
